SGHERZA, NICOLA
 Distribuzione geografica
Continente #
NA - Nord America 397
EU - Europa 200
AS - Asia 90
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 690
Nazione #
US - Stati Uniti d'America 396
IT - Italia 109
SE - Svezia 48
CN - Cina 31
SG - Singapore 22
HK - Hong Kong 19
GB - Regno Unito 10
DE - Germania 7
BE - Belgio 6
IE - Irlanda 5
RU - Federazione Russa 5
FR - Francia 4
IN - India 4
JP - Giappone 4
TR - Turchia 3
TW - Taiwan 3
CZ - Repubblica Ceca 2
EU - Europa 2
FI - Finlandia 2
TH - Thailandia 2
BR - Brasile 1
CA - Canada 1
KR - Corea 1
NL - Olanda 1
PH - Filippine 1
RO - Romania 1
Totale 690
Città #
Fairfield 46
Chandler 43
Nyköping 42
Woodbridge 29
Ashburn 26
Seattle 26
Houston 21
Singapore 20
Wilmington 17
Bari 15
Ann Arbor 14
Cambridge 14
New York 14
Lawrence 11
Inglewood 10
Des Moines 9
Roxbury 8
Gesualdo 7
Brussels 6
Santa Clara 6
Imbersago 5
Los Angeles 5
San Diego 5
Alcamo 4
Bitonto 4
Dublin 4
Milan 4
Modugno 4
Princeton 4
Avellino 3
Beijing 3
Chiswick 3
Florence 3
Guangzhou 3
Istanbul 3
Paris 3
Verona 3
Bengaluru 2
Bisceglie 2
Brno 2
Chiang Mai 2
Dearborn 2
Edinburgh 2
Fragagnano 2
Hefei 2
Itri 2
Jacksonville 2
London 2
Moscow 2
Munich 2
Nagano 2
Nanjing 2
Norwalk 2
Palermo 2
Rome 2
Taipei 2
Washington 2
Zhengzhou 2
Anaheim 1
Boardman 1
Bologna 1
Bucharest 1
Bunker Hill 1
Casoria 1
Changsha 1
Chennai 1
Florianópolis 1
Frankfurt am Main 1
Fuzhou 1
Groningen 1
Hebei 1
Helsinki 1
Hong Kong 1
Jiaxing 1
Kunming 1
Manila 1
Marcianise 1
Messina 1
Montreal 1
Naples 1
New Taipei 1
Noicattaro 1
Obata 1
Padova 1
Pavia 1
Queens 1
Redwood City 1
Shanghai 1
Siena 1
Taizhou 1
Triggiano 1
Valenzano 1
Wuhan 1
Yiwu 1
Totale 525
Nome #
null 96
Challenges and opportunities of MicroRNAs in lymphomas 90
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 88
null 68
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 68
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma 49
"Hemolysis, or not hemolysis, that is the question". Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency 34
What Is New in the Treatment of Smoldering Multiple Myeloma? 33
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 28
null 28
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study 26
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor 25
Occurrence of chronic myeloid leukemia in a patient with CDC73 gene deletion: “Chance or Causality?” 21
Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) 17
Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients 16
Implications of interleukin-6 (Il-6)-blockade for severe covid-19 infection in patients with multiple myeloma 16
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 15
Dasatinib first-line: Multicentric Italian experience outside clinical trials 14
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials 7
Serological response following BNT162b2 anti-SARS-COV-2 mRNA vaccination in hematopoietic stem cell transplantation patients 5
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases 2
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 2
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience 2
Latent tuberculosis infection detected by quantiferon-TB assay in patients with multiple myeloma receiving novel drugs: focus on reactivation prophylaxis in a retrospective, single-center study 2
Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease 2
Strengths and Weaknesses of Different Therapeutic Strategies for the Treatment of Patients with Multiple Myeloma Who Progress After the Frontline Use of Lenalidomide: A Narrative Review 1
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 1
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by “rete ematologica pugliese” 1
Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments 1
Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry 1
Totale 759
Categoria #
all - tutte 5.290
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.290


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202077 0 0 0 0 10 7 13 13 12 8 7 7
2020/202162 7 3 5 3 4 13 3 6 6 4 7 1
2021/2022120 21 8 0 8 6 9 14 5 5 7 21 16
2022/2023139 14 29 14 7 5 16 4 24 20 0 6 0
2023/2024187 26 31 26 8 15 28 29 5 0 0 6 13
2024/2025100 23 7 31 24 15 0 0 0 0 0 0 0
Totale 759